BioWorld

Feb. 10, 2009

Lundbeck Gains U.S. Foothold in $900M Deal for Ovation

Danish drugmaker H. Lundbeck A/S plans to buy U.S. biotech Ovation Pharmaceuticals in a proposed $900 million deal that would give the Copenhagen-based company access to the U.S. commercial market. (BioWorld Today) Read More

Investors Seeing Positive Side for Biotech in Bleak Economy

Panel: Keep Options Open to Survive Troubled Times

ViroPharma Shares Halved as Maribavir Fails Phase III Trial

Alliance Management Plays Important Role in Avoiding Failure

Lobbying Dynamics Reveal New Trends in Power

Gilded Age Can Be Ushered in by Biopartnered Gene Therapies

Corrections & Clarifications

Dynavax Soars on Possibility of Regulatory Path for Heplisav

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...